Gilead Sciences
Quarterly Financials
| Values in thousands | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|
Revenue | $7,925,000 | $7,769,000 | $7,081,000 | $6,667,000 |
Gross Profit | 6,882,000 | 6,200,000 | 5,580,000 | 5,127,000 |
EBITDA | 2,333,000 | 4,583,000 | 3,374,000 | 2,605,000 |
EBIT | 3,897,000 | 2,683,000 | 1,909,000 | |
Net Income | 2,183,000 | 3,052,000 | 1,960,000 | 1,315,000 |
Net Change In Cash | 7,925,000 | 7,769,000 | 7,081,000 | 6,667,000 |
Free Cash Flow | 3,326,000 | 3,961,000 | 720,000 | 1,653,000 |
Cash | 7,330,000 | 5,144,000 | 7,926,000 | |
Basic Shares | 1,253,000 | 1,254,000 | 1,255,000 | 1,259,000 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $29,443,000 | $28,754,000 | $27,116,000 | $27,281,000 |
Gross Profit | 25,523,000 | 22,503,000 | 27,116,000 | 21,624,000 |
EBITDA | 10,820,000 | 4,434,000 | 7,605,000 | 8,852,000 |
EBIT | 1,667,000 | 7,605,000 | 6,749,000 | |
Net Income | 8,510,000 | 480,000 | 5,665,000 | 4,592,000 |
Net Change In Cash | 29,443,000 | 28,754,000 | 27,116,000 | 27,281,000 |
Cost of Revenue | 137,000 | |||
Free Cash Flow | 9,456,000 | 10,305,000 | 7,421,000 | 8,344,000 |
Cash | 9,991,000 | 6,085,000 | 5,412,000 | |
Basic Shares | 1,255,000 | 1,255,000 | 1,258,000 | 1,262,000 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-03-31 | $0 |
2025-12-31 | $1.86 |
2025-09-30 | $2.47 |
2025-06-30 | $2.01 |
